Levosimendan exerts anticonvulsant properties against PTZ-induced seizures in mice through activation of nNOS/NO pathway: Role for K<inf>ATP</inf> channel by Amini-Khoei, Hossein. et al.
Life Sciences 168 (2017) 38–46
Contents lists available at ScienceDirect
Life Sciences
j ourna l homepage: www.e lsev ie r .com/ locate / l i fesc ieLevosimendan exerts anticonvulsant properties against PTZ-induced
seizures in mice through activation of nNOS/NO pathway: Role for
KATP channelMaziar Gooshe a,b,c,d, Mohammad Tabaeizadeh a,b, Ali Reza Aleyasin a,b, Payam Mojahedi a,b,
Keyvan Ghasemi a,b,c,d, Farbod Youseﬁ a,b, Ali Vafaei a,b, Hossein Amini-Khoei a,b,e,
Shayan Amiri a,b, Ahmad Reza Dehpour a,b,c,⁎
a Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
b Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran
c Brain and Spinal Injury Research Center, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
d Students' Scientiﬁc Research Center (SSRC), Tehran University of Medical Sciences, Tehran, Iran
e Department of Physiology and Pharmacology, School of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran⁎ Corresponding author at: Department of Pharmacolo
University of Medical Sciences, P.O. Box 13145-784, Tehra
E-mail addresses: Dr.mgooshe@gmail.com (M. Gooshe
(A.R. Dehpour).
http://dx.doi.org/10.1016/j.lfs.2016.11.006
0024-3205/© 2016 Elsevier Inc. All rights reserved.a b s t r a c ta r t i c l e i n f oArticle history:
Received 18 September 2016
Received in revised form 7 November 2016
Accepted 8 November 2016
Available online 14 November 2016Aims: Although approving new anticonvulsants was a major breakthrough in the ﬁeld of epilepsy control, so far
we have met limited success in almost one third of patients suffering from epilepsy and a deﬁnite and reliable
method is yet to be found. Levosimendan demonstrated neuroprotective effects and reduced mortality in condi-
tions in which seizure can be an etiology of death; however, the underlying neuroprotective mechanisms of
levosimendan still eludes us. In the light of evidence suggesting levosimendan can be a KATP channel opener
and nitrergic pathway activator, levosimendanmay exert antiseizure effects through KATP channels and nitrergic
pathway.
Mainmethods: In this study, the effects of levosimendan on seizure susceptibilitywas studied by PTZ-induced sei-
zures model in mice.
Key ﬁndings: Administration of a single effective dose of levosimendan signiﬁcantly increased seizures threshold
and the nitrite level in the hippocampus and temporal cortex. Pretreatment with noneffective doses of
glibenclamide (a KATP channel blocker) and L-NAME (a non-selective NOS inhibitor) neutralize the anticonvul-
sant and nitrite elevating effects of levosimendan. While 7-NI (a neural NOS inhibitor) blocked the anticonvul-
sant effect of levosimendan, Aminoguanidine (an inducible NOS inhibitor) failed to affect the anticonvulsant
effects of levosimendan. Cromakalim (aKATP channel opener) or L-arginine (anNOprecursor) augmented the an-
ticonvulsant effects of a subeffective dose of levosimendan.Moreover, co-administration of noneffective doses of
Glibenclamide and L-NAME demonstrated a synergistic effect in blocking the anticonvulsant effects of
levosimendan.
Signiﬁcance: Levosimendan has anticonvulsant effects possibly via KATP/nNOS/NO pathway activation in the hip-
pocampus and temporal cortex.
© 2016 Elsevier Inc. All rights reserved.Keywords:
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With a prevalence of 1–2%, epilepsies undoubtedly impose a major
burden upon patients and societies [1]. Despite major breakthroughs
in theﬁeld of epilepsy research, anti-seizuremedications donot provide
sufﬁcient seizure control in almost one-third of patients suffering from
epilepsy [2,3]. Thus, investigation on new evidence-based therapeuticalgy, School of Medicine, Tehran
n, Iran.
), Dehpour@yahoo.comstrategies is mandatory, and neuropharmacology can be a promising
ﬁeld for this purpose.
Levosimendan is a novel pyridazinone-dinitrile derivate, well-known
for positive inotropic effects through enhancing the sensitivity between
Ca+2 and myoﬁlaments and inhibiting the phosphodiesterase III activity
[4]. Some studies suggest possible impact of calcium sensitizers including
levosimendan on CNS, demonstrated as central symptoms such as head-
aches, vertigo, ﬂushing, and nausea [5]. Recent studies demonstrated that
levosimendan can improve the survival rates in calcium channel blockers
(CCBs) toxicity, which partly might be through seizure reduction as a
common consequence of CCB toxicity [6–8].
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to its inotropic effects, exerts cardio-protection, vasodilation, and anti-
oxidant activity through modulation of mitochondrial adenosine tri-
phosphate-sensitive potassium (KATP) channels and nitric oxide (NO)
production [9–12].
KATP channels are non-voltage dependent, inward-rectiﬁer potassi-
um channels, regulated by intracellular ATP/ADP ratio as a marker of
the cellular energy supply. Besides, various pharmacologic agents (e.g.,
cabergoline and glibenclamide) canmodulate the activity of these chan-
nels without affecting cellular ATP concentration [13–15]. Recent stud-
ies have found that the KATP channels have antiepileptic effects and help
to control neuronal excitability and seizure propagation [16–20].
NO is a gaseous neuronal messenger and neurotransmitter modula-
tor in the brain, synthesized by NO synthase (NOS) either constitutive
(eNOS, and nNOS) or inducible isoforms (iNOS) from L-arginine [21].
There are several studies reporting a controversial anticonvulsant or
pro-convulsant but, at the same time, a fundamental role for the
nitrergic system in the modulation of seizures [22–26].
The pivotal role of KATP channels and NO in both mechanism of ac-
tion of levosimendan and modulation of seizure thresholds raise the
possibility that levosimendan may affect the seizure susceptibility
through KATP and NO-dependent mechanisms. To this end, this study
aims to shed light on the effects of levosimendan on PTZ-induced sei-
zure threshold in mice as a model of generalized clonic seizures (GCS)
and then ascertain the nature of this effect by delineating themolecular
pathways involved in the exertion of this effect.
2. Methods and materials
2.1. Subjects
Swiss male mice at 12–16 weeks were used throughout this study.
The mice were housed at a constant temperature (23 °C) and relative
humidity (60%) in groups of 6–8 with free access to food and water
and a ﬁxed 12 h light/dark cycle. Procedures involving mice and their
care were conducted in conformity with the institutional guidelines
that are in compliancewith the national and international laws and pol-
icies. Each mouse was used only once, and each treatment group com-
prised of 6–8 animals. Additionally, all efforts were made to minimize
animal suffering and to use only the minimal number of animals re-
quired to produce reliable scientiﬁc data.
2.2. Pharmacological treatments
The following drugs were used in the study: levosimendan [a calci-
um sensitizer (Sigma, St Louis, MO, USA)], pentylenetetrazole (PTZ)
[GABAA receptor antagonist; (Sigma, UK)], L-arginine (L-Arg) [NO pre-
cursor; (Sigma, St Louis, MO, USA)], N(G)-nitro-L-arginine methyl
ester (L-NAME) [a non-selective NOS inhibitor; (Sigma, St Louis, MO,
USA)], 7-nitroindazole (7-NI) [a selective nNOS inhibitor; (Sigma, St
Louis, MO, USA)], aminoguanidine (AG) [an iNOS inhibitor; (Sigma, St
Louis, MO, USA)], Cromakalim [a KATP channel opener; (Sigma, St
Louis, MO, USA)], Glibenclamide [a KATP channel blocker; (Sigma, St
Louis, MO, USA)].
All drugs were freshly prepared prior to use, and injection volume
(10 mL·kg−1) was kept constant for in vivo experiments.
Levosimendan, L-NAME, 7- NI, AG, L-ARG, Cromakalim and
glibenclamide were administered intraperitoneally (i.p.). 7-NI was
suspended in a 1% aqueous solution of Tween 80 and all other drugs
were dissolved in normal saline. To assess clonic seizure, PTZ was ad-
ministered intravenously in the tail vein (0.5%, i.v.). The dosage selec-
tions, route of drug administration, and injection time of different
compounds were based on our previously published data, preliminary
experiments and pharmacokinetic considerations [20,22,24]. Control
mice were injected with the corresponding volume of vehicles beforePTZ-induced seizures. Pharmacological experiments were carried be-
tween 9.00 am and 2.00 pm.
2.3. Study design
309 mice were randomized into two categories. The ﬁrst category,
consisting of 35 groups, was used in seizure paradigm to assess the
PTZ-induced seizure threshold. Ten groups of mice were randomly
assigned to produce scientiﬁc and reliable data regarding levosimendan
effects on PTZ-induced seizures dose response and time course. In order
to delineate the role of KATP channel and nitrergic system on the anti-
convulsant properties of levosimendan mice were randomly assigned
to the following groups: 1) glibenclamide (0.5 mg·kg−1; i.p.); 2)
glibenclamide (1.0 mg·kg−1; i.p.); 3) glibenclamide (0.5 mg·kg−1;
i.p.) + levosimendan (2.0 mg·kg−1; i.p.); 4) glibenclamide
(1.0 mg·kg−1; i.p.) + levosimendan (2.0 mg·kg−1; i.p.); 5)
Cromakalim (0.5 mg·kg−1; i.p.); 6) Cromakalim (1.0 mg·kg−1; i.p.);
7) Cromakalim (0.5 mg·kg−1; i.p.) + levosimendan (0.2 mg·kg−1;
i.p.); 8) Cromakalim (1.0 mg·kg−1; i.p.) + levosimendan
(0.2 mg·kg−1; i.p.); 9) L-NAME (1.0 mg·kg−1; i.p.); 10) L-NAME
(5.0 mg·kg−1; i.p.); 11) L-NAME (1.0 mg·kg−1; i.p.) + levosimendan
(2.0 mg·kg−1; i.p.); 12) L-NAME (5.0 mg·kg−1; i.p.) + levosimendan
(2.0 mg·kg−1; i.p.); 13) L-ARG (30.0 mg·kg−1; i.p.); 14) L-ARG
(60.0 mg·kg−1; i.p.) 15) L-ARG (30.0 mg·kg−1; i.p.) + levosimendan
(0.2 mg·kg−1; i.p.); 16) L-ARG (60.0 mg·kg−1; i.p.) + levosimendan
(0.2 mg·kg−1; i.p.); 17) 7-NI (15.0 mg·kg−1; i.p.); 18) 7-NI
(30.0 mg·kg−1; i.p.); 19) 7-NI (15.0 mg·kg−1; i.p.) + levosimendan
(2.0 mg·kg−1; i.p.); 20) 7-NI (30.0 mg·kg−1; i.p.) + levosimendan
(2.0 mg·kg−1; i.p.); 21) AG (30.0 mg·kg−1; i.p.); 22) AG
(100.0 mg·kg−1; i.p.); 23) AG (30.0 mg·kg−1; i.p.) + levosimendan
(2.0 mg·kg−1; i.p.); 24) AG (100.0 mg·kg−1; i.p.) + levosimendan
(2.0 mg·kg−1; i.p.); 25) L-NAME (1.0 mg·kg−1; i.p.) + glibenclamide
(0.5 mg·kg−1; i.p.) + levosimendan (2.0 mg·kg−1; i.p.) (Table 1).
The second, consisting of 6 groups, was sacriﬁced to harvest brain
tissues for nitrite assays. To study the effects of levosimendan on NO
content in brain tissue mice were randomly assigned to the following
groups: 1) saline; 2) levosimendan (2.0 mg·kg−1; i.p.); 3) L-NAME
5.0 mg·kg−1; i.p.); 4) glibenclamide (1.0 mg·kg−1; i.p.); 5) L-NAME
(5.0 mg·kg−1; i.p.) + levosimendan (2.0 mg·kg−1; i.p.); 6)
glibenclamide (1.0 mg·kg−1; i.p.) + levosimendan (2.0 mg·kg−1; i.p.).
2.4. Seizure paradigm
In order to analyze the seizure susceptibility of mouse, we recruited
PTZ-induced seizure threshold as a model of GCS. The seizure paradigm
test was performed by researchers blinded to experimental conditions
using standardized test according to a protocol used previously in our
laboratory [22,27]. Following i.v. PTZ administration, eventually a se-
quence of seizure signs beginningwith twitch and progressing to clonus
and tonic limb extension is observed. In the present study, forelimb clo-
nus followed by full clonus of the bodywas used as the endpoint. In pre-
liminary experiments, forelimb clonus was found to be more sensitive
to levosimendan than other seizure phases. A 30-gauge, 3/4 in. butterﬂy
needle was inserted into the tail vein of unrestrained freely moving an-
imals, and the needle was secured with a piece of adhesive tape. The
needle was connected by a polyethylene tube to a 1 mL syringe
mounted on an infusion pump (NE 1000, New Era Pump System, Inc.).
PTZ solution (5 mg·mL−1) was infused at a constant rate of
1 mL·min−1. Infusion was halted at 1 min or when forelimb clonus
followed by full clonus of the body was observed, whichever occurred
ﬁrst. The animals were anesthetized by increasing carbon dioxide con-
centrations and killed by cervical displacement. The PTZ-induced sei-
zure threshold (mg·kg−1) was determined according to the following
formula: [infusion duration (min) ∗ infusion rate (mL·min−1) ∗ PTZ
concentration (mg·mL−1) ∗ 1000] / [weight of mouse (g)].
Table 1
Seizure paradigm groups: To assess the PTZ-induced seizure threshold in seizure paradigm 280mice were randomized into 35 categories. Ten groups of mice were randomly assigned to
produce scientiﬁc and reliable data regarding levosimendan effects on PTZ-induced seizures dose response and time course. In order to delineate the role of KATP channel and nitrergic
system on the anticonvulsant properties of levosimendan mice were randomly assigned to the 25 groups. KATP: adenosine triphosphate dependent potassium channels, PTZ:
pentylenetetrazole, L-NAME: Nω-nitro-L-arginine methyl ester hydrochloride, L-ARG: L-arginine, 7-NI: 7-nitroindazole, AG: aminoguanidine.
Group
numbers Aim
Drug 1 (dose, administered time before
PTZ injection)
Drug 2 (dose; administered time before
PTZ injection)
1–7 Dose-response relationship – Levosimendan (0.0, 0.1, 0.2, 0.5, 1, 2,
5 mg·kg−1; 90 min)
8–10 Time course – Levosimendan (2 mg·kg−1; 30, 60,
120 min)
11–14 Assess the role of KATP channels on the role of Levosimendan on seizures 1. Glibenclamide (0.5 mg·kg−1;
120 min)
–
2. Glibenclamide (1 mg·kg−1; 120 min) –
3. Glibenclamide (0.5 mg·kg−1;
120 min)
3. Levosimendan (2 mg·kg−1; 90 min)
4. Glibenclamide (1 mg·kg−1; 120 min) 4. Levosimendan (2 mg·kg−1; 90 min)
15–18 Assess the role of KATP channels on the role of Levosimendan on seizures 1. Cromakalim (0.5 μg·kg−1; 120 min) –
2. Cromakalim (1 μg·kg−1; 120 min) –
3. Cromakalim (0.5 μg·kg−1; 120 min) 3. Levosimendan (0.2 mg·kg−1; 90 min)
2. Cromakalim (1.0 μg·kg−1; 120 min) 4. Levosimendan (0.2 mg·kg−1; 90 min)
19–22 Assess the role of nitric oxide on the role of Levosimendan on seizures 1. L-NAME (1 mg·kg−1; 135 min) –
2. L-NAME (5 mg·kg−1; 135 min) –
3. L-NAME (1 mg·kg−1; 135 min) 3. Levosimendan (2 mg·kg−1; 90 min)
4. L-NAME (5 mg·kg−1; 135 min) 4. Levosimendan (2 mg·kg−1; 90 min)
23–26 Assess the role of nitric oxide on the role of Levosimendan on seizures 1. L-ARG (30.0 mg·kg−1; 135 min) –
2. L-ARG (60.0 mg·kg−1; 135 min) –
3. L-ARG (30.0 mg·kg−1; 135 min) 3. Levosimendan (0.2 mg·kg−1; 90 min)
4. L-ARG (60.0 mg·kg−1; 135 min) 4. Levosimendan (0.2 mg·kg−1; 90 min)
27–30 Assess the role of nNOS/NO on the role of Levosimendan on seizures 1. 7-NI (15 mg·kg−1; 135 min) –
2. 7-NI (30 mg·kg−1; 135 min) –
3. 7-NI (15 mg·kg−1; 135 min) 3. Levosimendan (2 mg·kg−1; 90 min)
4. 7-NI (30 mg·kg−1; 135 min) 4. Levosimendan (2 mg·kg−1; 90 min)
21–34 Assess the role of iNOS/NO on the role of Levosimendan on seizures 1. AG (30 mg·kg−1; 135 min) –
2. AG (100 mg·kg−1; 135 min) –
3. AG (30 mg·kg−1; 135 min) 3. Levosimendan (2 mg·kg−1; 90 min)
4. AG (100 mg·kg−1; 135 min) 4. Levosimendan (2 mg·kg−1; 90 min)
35 The interplay between nitrergic pathway and KATP channels on the role of
Levosimendan on seizures
1. L-NAME (1.0 mg·kg−1; 135 min) +
glibenclamide ( 0.5 mg·kg−1;
120 min)
1. Levosimendan (2 mg·kg−1; 90 min)
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The NO content in brain tissue wasmeasured in the form of nitrite, a
major stable product of NO using the Griess reagent, as previously de-
scribed [28]. Brieﬂy, brain homogenates were centrifuged and aliquots
of supernatants reactedwith the same volume of Griess reagent (1% sul-
fanilamide, 0.1% N-(1-naphthyl)-ethylenediamine dihydrochloride,
2.5% H3PO4; [Sigma, St. Louis, MO, USA]); each experimental mouse
hippocampus was lysed separately. Nitrite concentrations were quanti-
ﬁed spectrophotometrically at 540 nm using a standard curve plotted
for known concentrations of sodium nitrite. Each experimental group
consisted of 6–8 samples.
2.6. Statistical analysis
Data are expressed asmean± standard error of themean (S.E.M.) in
each experimental group. One-way ANOVA followed by Tukey's post
hoc multiple comparisons were used to analyze the data where appro-
priate. In all experimental groups, differences were considered statisti-
cally signiﬁcant in case the probability of type I error (p value) was
b0.05.
3. Results
3.1. Levosimendan affects PTZ-induced clonic seizure threshold
Our preliminary experiments revealed levosimendan dose-depen-
dent anticonvulsant effects on PTZ-induced seizures (Fig. 1.a).
Levosimendan demonstrated maximal anti-convulsive effects at thedose of 2 mg·kg−1 (p b 0.001 in comparison to the saline-treated con-
trol group). Besides, based on our data, levosimendan exerts its maxi-
mal effects on PTZ-induced seizure threshold within 90 min of
administration (p b 0.001 in comparison to the saline-treated control
group) (Fig. 1.b).
3.2. The role of KATP channels in modulation of the activity of levosimendan
on seizure threshold
In order to examine the role of KATP channels in modulation of the
activity of levosimendan on seizure threshold, the mice were treated
with glibenclamide (0.5 and 1 mg·kg−1; a KATP channel blocker), inde-
pendently and 30 min before administration of levosimendan
(2 mg·kg−1). Determination of PTZ-induced seizure threshold
120 min after independent injection of glibenclamide revealed no sig-
niﬁcant decrease in seizure threshold in comparison to the saline-treat-
ed control group. However, pre-treatment with glibenclamide
(1 mg·kg−1) 30 min before administration of levosimendan
(2mg·kg−1) and 120min before determination of PTZ-induced seizure
threshold reversed seizure threshold down to the saline-treated control
group (Fig. 2).
Additionally, the mice were treated with Cromakalim (0.5 and
1 μg·kg−1; a KATP channel opener), independently and 30 min before
administration of levosimendan (0.2 mg·kg−1). As shown in Fig. 3, in-
dependent administration of Cromakalim (0.5 and 1 μg·kg−1)
120 min before determination of PTZ-induced seizure threshold did
not change the seizure threshold in comparison to the saline-treated
control group. However, pre-treatment with Cromakalim (0.5 and
1 μg·kg−1) 30 min before administration of sub-effective dose of
levosimendan (0.2 mg·kg−1) and 120 min before determination of
Fig. 1. a. Effects of different doses of levosimendan (0.1, 0.2, 0.5, 1, 2, and 5 mg·kg−1) on PTZ-induced seizure threshold in mice. Levosimendan was administered 90 min before
determination of PTZ-induced seizure threshold. Data are expressed as the mean ± SEM of seizure threshold in each group. Each group consisted of 6–8 mice. **P b 0.01, ***P b 0.001,
compared with the saline-treated control group. b. Time course effects of levosimendan (2 mg·kg−1) on PTZ-induced seizure threshold in mice. Levosimendan was administered 30,
60, 90, or 120 min before determination of PTZ-induced seizure threshold, and its anticonvulsant effects were compared with the vehicle-treated control group (90 min before PTZ-
induced seizure). Data are expressed as mean ± SEM of seizure threshold in each group. Each group consisted of 6–8 mice. *P b 0.05, **P b 0.01, ***P b 0.001 in comparison to the
vehicle-treated control group.
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sant effects of sub-effective dose of levosimendan (0.2 mg·kg−1) in
comparison to the saline-treated control group (p b 0.01 for
0.5 μg·kg−1 of Cromakalim and p b 0.001 for 1 μg·kg−1 of Cromakalim).3.3. nNOS/NO pathway mediates the anticonvulsant effects of
levosimendan
In order to examine the role of nitrergic pathway in the anticonvul-
sant effects of levosimendan, nitrite levels were measured in brain ho-
mogenates, frontal, temporal, parietal and occipital cortices, the
hippocampus and the cerebellum of the mice treated with
levosimendan (2 mg·kg−1) (Table 2). Our data revealed that nitrite
levels were signiﬁcantly higher in the hippocampus (p b 0.001) and
temporal cortex (p b 0.001) of the mice treated with levosimendanFig. 2.Graded doses of glibenclamide (0.5 and 1mg·kg−1; a KATP channel blocker), which
independently did not alter PTZ-induced seizure threshold, decreased anticonvulsant
effects of levosimendan (2 mg·kg−1) down to the saline-treated control group.
Glibenclamide was administered 30 min before i.p. injection of levosimendan and
120 min before determination of PTZ-induced seizure threshold. Each group consisted of
6–8 mice. Data are expressed as the mean ± SEM seizure threshold in each group.
***P b 0.001, in comparison to the saline-treated control group.(2mg·kg−1) in comparison to the corresponding saline-treated control
groups.
Moreover, independent administration of L-NAME (1 and
5 mg·kg−1; a non-selective NOS inhibitor) 135 min before determina-
tion of PTZ-induced seizure threshold showed no signiﬁcant decrease
in seizure threshold in comparison to the saline-treated control group.
However, pre-treatment with L-NAME (5 mg·kg−1) 45 min before ad-
ministration of levosimendan (2 mg·kg−1) and 135 min before deter-
mination of PTZ-induced seizure threshold reversed seizure threshold
down to the saline-treated control group (Fig. 4). Also, independent ad-
ministration of L-NAME (5 mg·kg−1) showed no signiﬁcant change in
nitrite levels of hippocampus and temporal cortex of the mice in com-
parison to the corresponding saline-treated control groups. However,
pre-treatmentwith L-NAME (5mg·kg−1) 45min before administration
of levosimendan (2 mg·kg−1) reversed the increase of nitrite levels inFig. 3. Graded doses of Cromakalim (0.5 and 1 μg·kg−1; a KATP channel opener), which
independently did not alter PTZ-induced seizure threshold, potentiated anticonvulsant
effects of sub-effective dose of levosimendan (0.2 mg·kg−1) in comparison to the
saline-treated control group. Cromakalim was administered 30 min before i.p. injection
of levosimendan and 120 min before determination of PTZ-induced seizure threshold.
Each group consisted of 6–8 mice. Data are expressed as the mean ± SEM seizure
threshold in each group. **P b 0.01, ***P b 0.001, in comparison to the saline-treated
control group.
Fig. 4. Graded doses of L-NAME (1 and 5 mg·kg−1; a non-selective NOS inhibitor), which
independently did not alter PTZ-induced seizure threshold, decreased anticonvulsant
effects of levosimendan (2 mg·kg−1) down to the saline-treated control group. L-NAME
was administered 45 min before i.p. injection of levosimendan and 135 min before
determination of PTZ-induced seizure threshold. Each group consisted of 6–8 mice. Data
are expressed as the mean ± SEM seizure threshold in each group. ***P b 0.001, in
comparison to the saline-treated control group.
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saline-treated control groups (Table 3).
Furthermore, independent administration of L-Arg (30 and
60 mg·kg−1; NO precursor) 135 min before determination of PTZ-in-
duced seizure threshold did not change seizure threshold in comparison
to the saline-treated control group. However, pre-treatment with L-Arg
(30 and 60 mg·kg−1) 45 min before administration of sub-effective
dose of levosimendan (0.5 mg·kg−1) and 135 min before determina-
tion of PTZ-induced seizure threshold signiﬁcantly potentiated anticon-
vulsant effects of sub-effective dose of levosimendan (0.5 mg·kg−1) in
comparison to the saline-treated control group (p b 0.05 for
30 mg·kg−1 of L-Arg and p b 0.001 for 60 mg·kg−1 of L-Arg) (Fig. 5).
To distinguish the nitrergic pathway responsible for the anticonvul-
sant effects of levosimendan, the mice were treated with 7-NI (15 and
30 mg·kg−1; a selective nNOS inhibitor) and AG (30 and
100 mg·kg−1; an iNOS inhibitor), alone and 45 min before administra-
tion of levosimendan (2mg·kg−1). Administration of 7-NI andAG alone
135min before determination of PTZ-induced seizure threshold did not
change the seizure threshold in comparison to the saline-treated control
group (Figs. 6 and 7, respectively). Pre-treatment with 7-NI
(30 mg·kg−1) 45 min before administration of levosimendan
(2mg·kg−1) and 135min before determination of PTZ-induced seizure
threshold abolished the anticonvulsant effects of levosimendan to the
saline-treated control group (Fig. 6). However, pre-treatment with
AG (30 and 100 mg·kg−1) 45 min before administration of
levosimendan (2 mg·kg−1) and 135 min before determination of PTZ-
induced seizure threshold did not alter the anticonvulsant effects of
levosimendan (Fig. 7). Therefore, it seems the nNOS/NO pathway to
be responsible for the anticonvulsant effects of levosimendan.
3.4. The interplay between nitrergic pathway and KATP channels mediates
the anticonvulsant effects of levosimendan
As illustrated in Fig. 8, independent administration of sub-effective
doses of L-NAME (1 mg·kg−1; a non-selective NOS inhibitor) and
glibenclamide (0.5 mg·kg−1;a KATP channel blocker) 135 min and
120 min, respectively, before determination of PTZ-induced seizure
threshold did not affect seizure threshold in the mice in comparison to
the saline-treated control group. Neither pre-treatment with sub-effec-
tive dose of L-NAME (1 mg·kg−1) 45 min before administration of
levosimendan (2 mg·kg−1) and 135 min before determination of PTZ-
induced seizure threshold nor pre-treatment with sub-effective dose
of glibenclamide (0.5 mg·kg−1) 30 min before administration of
levosimendan (2 mg·kg−1) and 120 min before determination of PTZ-
induced seizure threshold could reduce anticonvulsant effects of
levosimendan. However, co-administration of sub-effective doses of L-
NAME (1 mg·kg−1) and glibenclamide (0.5 mg·kg−1) 45 min and
30min before administration of levosimendan(2mg·kg−1), respective-
ly and 135 min and 120 min before determination of PTZ-induced sei-
zure threshold respectively, decreased seizure threshold down to the
saline-treated control group. L-NAME and glibenclamide biological in-
teraction in diminishing the anticonvulsant effects of levosimendanTable 2
Nitrite levels (nM·mg−1) in brain homogenates, frontal, temporal, parietal and occipital cortice
(2 mg·kg−1). Nitrite levels were signiﬁcantly higher in the hippocampus and temporal cortex
corresponding brain regions of the saline-treated control group. Each group consisted of 6–8 m
Cerebral cortex
Frontal Temporal Parietal O
Saline 44.116 ± 1.993
(nM·mg−1)
75.018 ± 2.649
(nM·mg−1)
45.889 ± 2.386
(nM·mg−1)
68
(n
Levosimendan
(2 mg·kg−1)
43.489 ± 2.497
(nM·mg−1)
98.486 ± 1.296
(nM·mg−1)a
41.396 ± 3.958
(nM·mg−1)
63
(n
a P b 0.001 in comparison to nitrite levels in the temporal cortex of the saline-treated contro
b P b 0.001 in comparison to nitrite levels in the hippocampus of the saline-treated control g
c P b 0.01 in comparison to nitrite levels in brain homogenates of the saline-treated controlcan indicate the interplay between nitrergic pathway and KATP channels
in mediating the anticonvulsant effects of levosimendan.
In order to determine the underlying interaction between nitrergic
pathway and KATP channels, resulting in anticonvulsant effects of
levosimendan, nitrite levels were measured in the hippocampus and
temporal cortex of the mice after having been treated with
glibenclamide (1 mg·kg−1; a KATP channel blocker), independently
and 30min before administration of levosimendan (2mg·kg−1). Nitrite
assay showed no signiﬁcant change in nitrite levels in the hippocampus
and temporal cortex of the mice treated with glibenclamide
(1 mg·kg−1) alone in comparison to the corresponding saline-treated
control groups. However, pre-treatment of themicewith glibenclamide
(1 mg·kg−1) 30 min before administration of levosimendan caused ni-
trite levels in the hippocampus and temporal cortex of the mice to de-
crease down to the corresponding saline-treated control groups
(Table 3).4. Discussion
Themain results of this study are two-fold. First, levosimendan has a
dose- and time-dependent anticonvulsant effects on PTZ-induced clonic
seizures. Second, levosimendan exerts its anticonvulsant effects on PTZ-
induced clonic seizures through activation of KATP channels, whichs, the hippocampus and the cerebellum of themice treated with saline and levosimendan
of the mice treated with levosimendan (2 mg·kg−1) in comparison to nitrite levels in the
ice.
Hippocampus Cerebellum Brain homogenatesccipital
.339 ± 1.749
M·mg−1)
56.497 ± 1.694
(nM·mg−1)
33.229 ± 1.387
(nM·mg−1)
42.497 ± 2.486
(nM·mg−1)
.622 ± 2.795
M·mg−1)
73.497 ± 1.738
(nM·mg−1)b
35.259 ± 3.628
(nM·mg−1)
54.397 ± 1.694
(nM·mg−1)c
l group.
roup.
group.
Table 3
Nitrite levels (nM·mg−1) in the temporal cortex and hippocampus of the mice treated with saline, levosimendan (2 mg·kg−1), L-NAME (5 mg·kg−1; a non-selective NO inhibitor),
glibenclamide (1 mg·kg−1; a KATP channel blocker), L-NAME (5 mg·kg−1) and levosimendan (2 mg·kg−1), glibenclamide (1 mg·kg−1) and levosimendan (2 mg·kg−1). Independent
administration of L-NAME (5mg·kg−1) and glibenclamide (1 mg·kg−1) did not change nitrite levels in the temporal cortex and hippocampus of the mice in comparison to nitrite levels
in the corresponding brain regions of the saline-treated control group. However, pre-treatment with L-NAME (5 mg·kg−1) 45 min before administration of levosimendan (2 mg·kg−1)
and also pre-treatmentwith glibenclamide (1mg·kg−1) 30minbefore administration of levosimendan (2mg·kg−1) reversednitrite levels of the temporal cortex and hippocampus of the
mice down to the nitrite levels in the corresponding brain regions of the saline-treated control group. Each group consisted of 6–8 mice.
Saline
Levosimendan
(2 mg·kg−1)
L-NAME
(5 mg·kg−1)
Glibenclamide
(1 mg·kg−1)
L-NAME (5 mg·kg−1) +
Levosimendan (2 mg·kg−1)
Glibenclamide (1 mg·kg−1) +
Levosimendan (2 mg·kg−1)
Temporal
cortex
75.018 ± 2.649
(nM·mg−1)
98.486 ± 1.296
(nM·mg−1)a
73.592 ± 1.285
(nM·mg−1)
71.385 ± 2.958
(nM·mg−1)
77.012 ± 0.947 (nM·mg−1) 78.379 ± 3.226 (nM·mg−1)
Hippocampus 56.497 ± 1.694
(nM·mg−1)
73.497 ± 1.738
(nM·mg−1)b
58.147 ± 3.519
(nM·mg−1)
56.594 ± 1.481
(nM·mg−1)
59.883 ± 0.439 (nM·mg−1) 52.297 ± 2.559 (nM·mg−1)
a P b 0.001 in comparison to nitrite levels in the temporal cortex of the saline-treated control group.
b P b 0.001 in comparison to nitrite levels in the hippocampus of the saline-treated control group.
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and temporal cortex.
PTZ-induced clonic seizure threshold used in this study is a well-
established paradigm to assess forebrain regulated seizures susceptibil-
ity, representing an animal model of clonic seizures in humans. PTZ
Binding to the GABAA-gated chloride ionophore results in dis-inhibition
of GABAergic transmission and consequent general dis-inhibitory state
[29–32]. The dose- and time-dependent effects of levosimendan in in-
creasing this threshold implies potential clinical beneﬁt and is in accor-
dance with suggestions that levosimendan may act as a modulator in
some pathways in the brain [33]. The acute systemic effects of
levosimendan at comparable doses have been reported to be neuro-
protective effects against various neuronal injury including global tran-
sient ischaemia/hypoxia, reperfusion injury and traumatic brain injury
[34–36]. The mechanisms of reported neuro-protective effects of
levosimendan still elude us and require further investigations.
There are several studies reporting levosimendan as a KATP opener,
especially in cardiovascular system such as cardiac myocytes [10,37],
isolated mesenteric artery myocytes [38], coronary arteries [39,40]
and human portal and saphenous veins [41,42].Fig. 5. Graded doses of L-Arg (30 and 60 mg·kg−1; NO precursor), which independently
did not alter PTZ-induced seizure threshold, potentiated anticonvulsant effects of sub-
effective dose of levosimendan (0.2 mg·kg−1) in comparison to the saline-treated
control group. L-Arg was administered 45 min before i.p. injection of levosimendan and
135 min before determination of PTZ-induced seizure threshold. Each group consisted of
6–8 mice. Data are expressed as the mean ± SEM seizure threshold in each group.
*P b 0.05, ***P b 0.001, in comparison to the saline-treated control group.In linewith these ﬁndings, there aremountains of evidence suggest-
ing the important role of KATP channels in the modulation of neural ex-
citability and consequently seizure threshold in several in vivo and in
vitro studies. KATP channel openers have been shown to decrease neu-
rons excitability in hippocampus [16,18] and have anti-epileptic effects
in drug induced epilepsy [43]. In this regards, knockout studies have re-
vealed that Kir6.2 (a subunit of KATP channels)-deﬁcient mice are more
prone to generalized seizures after brief hypoxia [44]. Moreover, it has
been reported that lacks in expression of either the SUR1 (a subunit of
KATP channels) or the Kir6.1 (a subunit of KATP channels) results in
more susceptibility to kainic acid-induced seizures in mice [18]. On
the other hand, over-expression of SUR1 subunit of KATP channels in
the forebrain of mice can reduce the susceptibility to kainic acid-in-
duced seizures [45]. It has been suggested that expression of functional
Kir6.1/SUR1 channels can inhibit neuronal hyper-excitability possibly
by limiting excitatory release of glutamate in CA3 of hippocampus
[46]. Indeed, there are some reports suggesting that activation of KATP
channels through KATP channel openers such as Cromakalim could
exert anticonvulsant properties in the PTZ-induced seizures, while
blocking KATP channels by glibenclamide could exert pro-convulsant
properties [19,20].Fig. 6. Graded doses of 7-NI (15 and 30 mg·kg−1; a selective nNOS inhibitor), which
independently did not alter PTZ-induced seizure threshold, reversed anticonvulsant
effects of levosimendan (2 mg·kg−1) to the saline-treated control group. 7-NI was
administered 45 min before i.p. injection of levosimendan and 135 min before
determination of PTZ-induced seizure threshold. Each group consisted of 6–8 mice. Data
are expressed as the mean ± SEM seizure threshold in each group. ***P b 0.001, in
comparison to the saline-treated control group.
Fig. 7. Independent administration of graded doses of AG (30 and 100 mg·kg−1; a
selective iNOS inhibitor) did not alter PTZ-induced seizure threshold in comparison to
the saline-treated control group. Also, Pre-treatment with different doses of AG (30 and
100 mg·kg−1) 45 min before i.p. injection of levosimendan and 135 min before
determination of PTZ-induced seizure threshold could not alter anticonvulsant effects of
levosimendan (2 mg·kg−1). Each group consisted of 6–8 mice. Data are expressed as
the mean ± SEM seizure threshold in each group. ***P b 0.001, in comparison to the
saline-treated control group.
44 M. Gooshe et al. / Life Sciences 168 (2017) 38–46Altogether our results indicate levosimendan to have anticonvulsant
effects through activation of KATP channels; its anticonvulsant effects
being abolished by glibenclamide (KATP inhibitor) down to the control
group aswell as its sub-effective dose being potentiated by Cromakalim
(KATP opener) to a signiﬁcant rise in seizure threshold in comparison to
the control group.Fig. 8. Independent administration of sub-effective doses of L-NAME (1 mg·kg−1; a non-selec
30 min respectively before determination of PTZ-induced seizure threshold did not alter seizu
effective doses of L-NAME (1 mg·kg−1) or glibenclamide (0.5 mg·kg−1) 45 min and 30 min b
respectively min before determination of PTZ-induced seizure threshold respectively did not a
doses of L-NAME (1 mg·kg−1) and glibenclamide (0.5 mg·kg−1) 54 min and 30 min resp
respectively before determination of PTZ-induced seizure threshold reversed anticonvulsant e
6–8 mice. Data are expressed as the mean ± SEM seizure threshold in each group. ***P b 0.001There are several lines of evidence suggesting themodulatory role of
nitrergic system in regulation of seizure threshold. The direction of its
effect is perpendicular to NO production source and region, other neu-
rotransmitters involved, and seizure types or models [22–26]. There
are some reports indicating activation of nitrergic system either by
pharmacological agents or pathological conditions could exert anticon-
vulsant properties in PTZ-induced seizures [24,47]. Conversely, there
are ample evidence highlighting NO over-production caused by activa-
tion of NOS enzymes or administration of maximal doses of NO precur-
sor L-Arg could exert epileptogenic effects in seizure paradigms induced
by GABA inhibition, such as PTZ-induced seizures [22,48].
To further elucidate the downstreamevents involved in the anticon-
vulsant effects of levosimendan, in the ﬁrst step we investigated the
possible involvement of nitrergic pathway by measuring nitrite levels
in the brain homogenates of the mice and in speciﬁc regions including
cortical regions (frontal, parietal, temporal and occipital), the hippo-
campus, and the cerebellum following i.p. injection of levosimendan.
Our data indicated signiﬁcant increased levels of nitrite in temporal cor-
tical region and the hippocampus of the mice, which received a single
dose of levosimendan in comparison to control. There are constant en-
deavors to clearly determine the role of brain structures in the genera-
tion of GCS. In a recent study, it has been demonstrated that the NO
levels in all brain regions especially temporal cortex contribute to PTZ-
induced seizures threshold [49].
Furthermore, we demonstrated that anticonvulsant effects of
levosimendan could be completely reversed down to seizure threshold
of control group by the means of L-NAME, or 7-NI pretreatments,
whereas AG did not alter the seizure threshold signiﬁcantly. Moreover,
L-arginine pre-treatment augments the sub-effective dose of
levosimendan to signiﬁcantly increase the seizure threshold. Indeed, ni-
trite assays in temporal cortical region and the hippocampus of themice
revealed that nitrite level increase followed by anticonvulsant dose of
levosimendan is abolished by pre-treatment with L-NAME, or 7-NI. On
the other hand, administration of L-Arg before a sub-effective dose of
levosimendan evoked a signiﬁcant rise in nitrite levels.tive NOS inhibitor) and glibenclamide (0.5 mg·kg−1; a KATP channel blocker) 45 min and
re threshold in comparison to the saline-treated control group. Pre-treatment with sub-
efore i.p. injection of levosimendan (2 mg·kg−1) respectively and 135 min and 120 min
lter anticonvulsant effects of levosimendan. However, co-administration of sub-effective
ectively before i.p. injection of levosimendan (2 mg·kg−1) and 135 min and 120 min
ffects of levosimendan down to the saline-treated control group. Each group consisted of
, in comparison to the saline-treated control group.
45M. Gooshe et al. / Life Sciences 168 (2017) 38–46Finally, our results demonstrated that sub-effective doses of these
compounds neither changed the seizure threshold, nor the anticonvul-
sant effects of levosimendan; however, their co-administration blocked
the anticonvulsant effects of levosimendan. These results may imply on
a biological interaction between KATP channels and nitrergic pathway
can modulate the anticonvulsant properties of levosimendan.
Some of previous studies claim that NO is a downstream product of
signaling pathways secondary to KATP channels [50,51], while others
propose that NO can induce hyperpolarization of mitochondrial or cell
membrane through opening the KATP channels [52,53]. Nitrite assay re-
veals that administration of glibenclamide (a KATP channel antagonist)
before levosimendan prevented the signiﬁcant rise of nitrite levels in
temporal cortex and hippocampus. Hence, our results support the idea
that activation of KATP channels by levosimendan may stimulate
nitrergic pathway.
Summing up, our ﬁndings for the ﬁrst time elucidated the role of
levosimendan in modulation of seizure threshold as a calcium sensitizer
drug.We revealed the novel modulatory role of KATP/nNOS/NO activation
in the hippocampus and temporal cortex in exertion of the anticonvulsant
effects of levosimendan. Although the present ﬁndings need further in-
vestigation by experimental studies on other models of seizures and epi-
lepsies, these ﬁndings add an important insight into the mechanism of
neuroprotective effects of levosimendan and shall pave the way for inno-
vative strategies in management of patients inﬂicted by comorbidity of
seizures and heart failures (it has been suggested some of people have
treatment resistant seizures, could have undiagnosed heart disease [54];
on the other hand heart failure can be a common etiology of sudden
death after seizures [55] or drug toxicities, such as CCBs. It also remains
an open question, whether KATP channels openers and levosimendan in
speciﬁc, are appropriate choices for treatment of epilepsy or can be an ad-
junctive therapy alongside other antiepileptic drugs.
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